Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Titel:
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Auteur:
Papp, Kim A Langley, Richard G Lebwohl, Mark Krueger, Gerald G Szapary, Philippe Yeilding, Newman Guzzo, Cynthia Hsu, Ming-Chun Wang, Yuhua Li, Shu Dooley, Lisa T Reich, Kristian